CASI Pharmaceuticals analyst ratings
CASI Pharmaceuticals analyst ratings
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $4.00 to $21.00. The current price CASI Pharmaceuticals (CASI) is trading at is $3.71, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/03/2022 | 466.04% | BTIG | $4 → $21 | Maintains | Buy |
| 05/16/2022 | -19.14% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 05/18/2021 | 7.82% | BTIG | → $4 | Initiates Coverage On | → Buy |
| 05/14/2021 | 7.82% | HC Wainwright & Co. | $3.5 → $4 | Maintains | Buy |
| 04/26/2021 | 2.43% | Mizuho | → $3.8 | Initiates Coverage On | → Buy |
| 10/23/2020 | 34.77% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 03/24/2020 | -5.66% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 06/03/2022 | 466.04% | BTIG | 4 美元 → 21 美元 | 维护 | 买 |
| 05/16/2022 | -19.14% | HC Wainwright & Co. | 4 美元 → 3 美元 | 维护 | 买 |
| 05/18/2021 | 7.82% | BTIG | → 4 美元 | 启动覆盖范围开启 | → 购买 |
| 05/14/2021 | 7.82% | HC Wainwright & Co. | 3.5 美元 → 4 美元 | 维护 | 买 |
| 04/26/2021 | 2.43% | 瑞穗市 | → 3.8 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 10 月 23 日 | 34.77% | 奥本海默 | → 5 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2020 年 3 月 24 日 | -5.66% | HC Wainwright & Co. | 7 美元 → 3.5 美元 | 维护 | 买 |
CASI Pharmaceuticals Questions & Answers
CASI 制药问题与解答
The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by BTIG on June 3, 2022. The analyst firm set a price target for $21.00 expecting CASI to rise to within 12 months (a possible 466.04% upside). 2 analyst firms have reported ratings in the last year.
BTIG于2022年6月3日公布了卡西制药（纳斯达克股票代码：CASI）的最新目标股价。该分析公司将目标股价定为21.00美元，预计CASI将在12个月内升至12个月内（可能上涨466.04％）。去年有两家分析公司公布了评级。
The latest analyst rating for CASI Pharmaceuticals (NASDAQ: CASI) was provided by BTIG, and CASI Pharmaceuticals maintained their buy rating.
CASI Pharmicals（纳斯达克股票代码：CASI）的最新分析师评级由BTIG提供，CASI Pharmicals维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on June 3, 2022 so you should expect the next rating to be made available sometime around June 3, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与CASI Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。CASI Pharmicals的最新评级是在2022年6月3日发布的，因此您应该预计下一个评级将在2023年6月3日左右公布。
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $4.00 to $21.00. The current price CASI Pharmaceuticals (CASI) is trading at is $3.71, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的CASI Pharmicals（CASI）评级维持不变，目标股价为4.00美元至21.00美元。CASI Pharmicals（CASI）目前的交易价格为3.71美元，超出了分析师的预期区间。
